Decreased serum levels of adiponectin in subjects with autism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 3, 2010, Pages 455-458

  Fujita Shimizu, Azusa ^a   Suzuki, Katsuaki ^a   Nakamura, Kazuhiko ^a   Miyachi, Taishi ^a   Matsuzaki, Hideo ^b   Kajizuka, Masanobu ^a   Shinmura, Chie ^a   Iwata, Yasuhide ^a   Suda, Shiro ^a   Tsuchiya, Kenji J ^a   Matsumoto, Kaori ^a   Sugihara, Genichi ^a   Iwata, Keiko ^a   Yamamoto, Shigeyuki ^a   Tsujii, Masatsugu ^a,c   Sugiyama, Toshiro ^d   Takei, Nori ^a   Mori, Norio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHUKYO UNIVERSITY   (Japan)

^d AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

Author keywords

Adiponectin; Autism; Inflammatory events; Serum

Indexed keywords

ADIPONECTIN;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INTERVIEW; MALE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; SOCIAL INTERACTION;

ADIPONECTIN; ADOLESCENT; AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 77949659662     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.12.020     Document Type: Article

References (23)

1. User's guide for the structured clinical interview for DSM-IV axis I disorders SCID-1: clinician version 1997, American Psychiatric Association, American Psychiatric Press, Washington DC.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. fourth edition, text revision.
3. Ashwood P., Enstrom A., Krakowiak P., Hertz-Picciotto I., Hansen R.L., Croen L.A., et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008, 204:149-153.
4. Baird G., Cass H., Slonims V. Diagnosis of autism. BMJ 2003, 327:488-493.
5. Boris M., Kaiser C.C., Goldblatt A., Elice M.W., Edelson S.M., Adams J.B., et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation 2007, 4:3.
6. Cohly H.H., Panja A. Immunological findings in autism. Int Rev Neurobiol 2005, 71:317-341.
7. Jyonouchi H., Sun S., Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001, 120:170-179.
8. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
9. Kokubu N., Tsuchihashi K., Yuda S., Hase M., Eguchi M., Wakabayashi T., et al. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J 2006, 70:1451-1456.
10. Li X., Chauhan A., Sheikh A.M., Patil S., Chauhan V., Li X.M., et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009, 207:111-116.
11. Licinio J., Alvarado I., Wong M.L. Autoimmunity in autism. Mol Psychiatry 2002, 7:329.
12. Lord C., Rutter M., Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24:659-685.
13. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
14. McDougle C.J., Erickson C.A., Stigler K.A., Posey D.J. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 66(Suppl. 10):9-18.
15. Neumeier M., Weigert J., Buettner R., Wanninger J., Schäffler A., Müller A.M., et al. Detection of adiponectin in cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab 2007, 293:965-969.
16. Okada K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya J.K., et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:187-190.
17. Pan W., Kastin A.J. Adipokines and the blood-brain barrier. Peptides 2007, 28:1317-1330.
18. Pardo C.A., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005, 17:485-495.
19. Shetty S., Kusminski C.M., Scherer P.E. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009, 30:234-239.
20. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
21. Spranger J., Verma S., Gohring I., Bobbert T., Seifert J., Sindler A.L., et al. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006, 55:141-147.
22. Tsuchiya J.K., Hashimoto K., Iwata Y., Tsujii M., Sekine Y., Sugihara G., et al. Decreased serum levels of platelet-endothelial adhesion molecule (PECAM-1) in subjects with high-functioning autism: a negative correlation with head circumference at birth. Biol Psychiatry 2007, 62:1056-1058.
23. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362-2374.